At the bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases

Journal of Leukocyte Biology

Volumn 99, Issue 2, 2016, Pages 265-278

  Barnado, April ^a   Crofford, Leslie J ^a   Oates, Jim C ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Autoimmunity; Systemic lupus erythematosus; Type I IFN

Indexed keywords

BIOLOGICAL MARKER; ACETYLCYSTEINE; ALPHA INTERFERON; ANTIMALARIAL AGENT; AUTOANTIGEN; DEOXYRIBONUCLEASE I; HYDROLASE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PEPTIDYLARGININE DEIMINASE TYPE IV; VITAMIN D;

ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; DISEASE ACTIVITY; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR TRAP; HUMAN; MOTION SICKNESS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSLATIONAL RESEARCH; ANTAGONISTS AND INHIBITORS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; APOPTOSIS; AUTOIMMUNE DISEASES; BIOSYNTHESIS; COMPLICATION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULARLY TARGETED THERAPY; NEUTROPHIL; PREGNANCY; PREGNANCY COMPLICATIONS; PROCEDURES; PROTEIN PROCESSING; THROMBOPHILIA; THROMBOSIS; TRENDS;

ACETYLCYSTEINE; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL; ANTIMALARIALS; APOPTOSIS; ATHEROSCLEROSIS; AUTOANTIGENS; AUTOIMMUNE DISEASES; BIOMARKERS; DEOXYRIBONUCLEASE I; EXTRACELLULAR TRAPS; FEMALE; HUMANS; HYDROLASES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; NEUTROPHILS; PREGNANCY; PREGNANCY COMPLICATIONS; PROTEIN PROCESSING, POST-TRANSLATIONAL; THROMBOPHILIA; THROMBOSIS; TRANSLATIONAL MEDICAL RESEARCH; VITAMIN D;

EID: 84957634557     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5BT0615-234R     Document Type: Article

References (74)

1. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y., Zychlinsky, A. (2004) Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535.
2. Takei, H., Araki, A., Watanabe, H., Ichinose, A., Sendo, F. (1996) Rapid killing of human neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied by changes different from typical apoptosis or necrosis. J. Leukoc. Biol. 59, 229-240.
3. Grayson, P. C., Kaplan, M. J. (2016) At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J. Leukoc. Biol. 99, 253-264.
4. Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y. H., Homey, B., Cao, W.,Wang, Y. H., Su, B., Nestle, F. O., Zal, T., Mellman, I., Schröder, J. M., Liu, Y. J., Gilliet, M. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564-569.
5. Kessenbrock, K., Krumbholz, M., Schönermarck, U., Back, W., Gross, W. L., Werb, Z., Gröne, H. J., Brinkmann, V., Jenne, D. E. (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623-625.
6. Villanueva, E., Yalavarthi, S., Berthier, C. C., Hodgin, J. B., Khandpur, R., Lin, A. M., Rubin, C. J., Zhao, W., Olsen, S. H., Klinker, M., Shealy, D., Denny, M. F., Plumas, J., Chaperot, L., Kretzler, M., Bruce, A. T., Kaplan, M. J. (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538-552.
7. Khandpur, R., Carmona-Rivera, C., Vivekanandan-Giri, A., Gizinski, A., Yalavarthi, S., Knight, J. S., Friday, S., Li, S., Patel, R. M., Subramanian, V., Thompson, P., Chen, P., Fox, D. A., Pennathur, S., Kaplan, M. J. (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra40.
8. Leffler, J., Stojanovich, L., Shoenfeld, Y., Bogdanovic, G., Hesselstrand, R., Blom, A. M. (2014) Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clin. Exp. Rheumatol. 32, 66-70.
9. Yalavarthi, S., Gould, T. J., Rao, A. N., Mazza, L. F., Morris, A. E., Núñez-Álvarez, C., Hernández-Ramírez, D., Bockenstedt, P. L., Liaw, P. C., Cabral, A. R., Knight, J. S. (2015) Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 67, 2990-3003.
10. Branzk, N., Papayannopoulos, V. (2013) Molecular mechanisms regulating NETosis in infection and disease. Semin. Immunopathol. 35, 513-530.
11. Ermert, D., Urban, C. F., Laube, B., Goosmann, C., Zychlinsky, A., Brinkmann, V. (2009) Mouse neutrophil extracellular traps in microbial infections. J. Innate Immun. 1, 181-193.
12. Rönnblom, L. (2010) Potential role of IFNa in adult lupus. Arthritis Res. Ther. 12 (Suppl 1), S3.
13. Hakkim, A., Fürnrohr, B. G., Amann, K., Laube, B., Abed, U. A., Brinkmann, V., Herrmann, M., Voll, R. E., Zychlinsky, A. (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA 107, 9813-9818.
14. Nakazawa, D., Shida, H., Tomaru, U., Yoshida, M., Nishio, S., Atsumi, T., Ishizu, A. (2014) Enhanced formation and disordered regulation of NETs in myeloperoxidase-ANCA-associated microscopic polyangiitis. J. Am. Soc. Nephrol. 25, 990-997.
15. Leffler, J., Martin, M., Gullstrand, B., Tydén, H., Lood, C., Truedsson, L., Bengtsson, A. A., Blom, A. M. (2012) Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 188, 3522-3531.
16. Leffler, J., Gullstrand, B., Jönsen, A., Nilsson, J. A., Martin, M., Blom, A. M., Bengtsson, A. A. (2013) Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res. Ther. 15, R84.
17. Nakazawa, D., Tomaru, U., Yamamoto, C., Jodo, S., Ishizu, A. (2012) Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis. Front. Immunol. 3, 333.
18. Sur Chowdhury, C., Giaglis, S., Walker, U. A., Buser, A., Hahn, S., Hasler, P. (2014) Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res. Ther. 16, R122.
19. Xiao, H., Heeringa, P., Hu, P., Liu, Z., Zhao, M., Aratani, Y., Maeda, N., Falk, R. J., Jennette, J. C. (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. 110, 955-963.
20. Xiao, H., Heeringa, P., Liu, Z., Huugen, D., Hu, P., Maeda, N., Falk, R. J., Jennette, J. C. (2005) The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol. 167, 39-45.
21. Kelley, J. M., Monach, P. A., Ji, C., Zhou, Y., Wu, J., Tanaka, S., Mahr, A. D., Johnson, S., McAlear, C., Cuthbertson, D., Carette, S., Davis, Jr., J. C., Dellaripa, P. F., Hoffman, G. S., Khalidi, N., Langford, C. A., Seo, P., St Clair, E. W., Specks, U., Stone, J. H., Spiera, R. F., Ytterberg, S. R., Merkel, P. A., Edberg, J. C., Kimberly, R. P. (2011) IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc. Natl. Acad. Sci. USA 108, 20736-20741.
22. Xu, J., Zhang, X., Pelayo, R., Monestier, M., Ammollo, C. T., Semeraro, F., Taylor, F. B., Esmon, N. L., Lupu, F., Esmon, C. T. (2009) Extracellular histones are major mediators of death in sepsis. Nat. Med. 15, 1318-1321.
23. Fuchs, T. A., Brill, A., Duerschmied, D., Schatzberg, D., Monestier, M., Myers, Jr., D. D., Wrobleski, S. K., Wakefield, T. W., Hartwig, J. H., Wagner, D. D. (2010) Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. USA 107, 15880-15885.
24. Von Scheven, E., Lu, T. T., Emery, H. M., Elder, M. E., Wara, D. W. (2003) Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum. 49, 862-865.
25. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. (2005) Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351-361.
26. Ma, K., Simantov, R., Zhang, J. C., Silverstein, R., Hajjar, K. A., McCrae, K. R. (2000) High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J. Biol. Chem. 275, 15541-15548.
27. Allen, K. L., Fonseca, F. V., Betapudi, V., Willard, B., Zhang, J., McCrae, K. R. (2012) A novel pathway for human endothelial cell activation by antiphospholipid/anti-b2 glycoprotein I antibodies. Blood 119, 884-893.
28. Sorice, M., Circella, A., Griggi, T., Garofalo, T., Nicodemo, G., Pittoni, V., Pontieri, G. M., Lenti, L., Valesini, G. (1996) Anticardiolipin and antibeta 2-GPI are two distinct populations of autoantibodies. Thromb. Haemost. 75, 303-308.
29. Deane, K. D., Norris, J. M., Holers, V. M. (2010) Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum. Dis. Clin. North Am. 36, 213-241.
30. Kidd, B. A., Ho, P. P., Sharpe, O., Zhao, X., Tomooka, B. H., Kanter, J. L., Steinman, L., Robinson, W. H. (2008) Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res. Ther. 10, R119.
31. Lundberg, K., Nijenhuis, S., Vossenaar, E. R., Palmblad, K., van Venrooij, W. J., Klareskog, L., Zendman, A. J., Harris, H. E. (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 7, R458-R467.
32. Li, P., Li, M., Lindberg, M. R., Kennett, M. J., Xiong, N., Wang, Y. (2010) PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853-1862.
33. Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., Bruce, A. T. (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187, 490-500.
34. Lande, R., Ganguly, D., Facchinetti, V., Frasca, L., Conrad, C., Gregorio, J., Meller, S., Chamilos, G., Sebasigari, R., Riccieri, V., Bassett, R., Amuro, H., Fukuhara, S., Ito, T., Liu, Y. J., Gilliet, M. (2011) Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19.
35. Zhang, S., Lu, X., Shu, X., Tian, X., Yang, H., Yang, W., Zhang, Y., Wang, G. (2014) Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. Intern. Med. 53, 2763-2771.
36. Carmona-Rivera, C., Zhao, W., Yalavarthi, S., Kaplan, M. J. (2015) Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann. Rheum. Dis. 74, 1417-1424.
37. Smith, C. K., Vivekanandan-Giri, A., Tang, C., Knight, J. S., Mathew, A., Padilla, R. L., Gillespie, B. W., Carmona-Rivera, C., Liu, X., Subramanian, V., Hasni, S., Thompson, P. R., Heinecke, J. W., Saran, R., Pennathur, S., Kaplan, M. J. (2014) Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol. 66, 2532-2544.
38. Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H.; The Committee on Prognosis Studies in SLE. (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 35, 630-640.
39. Grayson, P. C., Carmona-Rivera, C., Xu, L., Lim, N., Gao, Z., Asare, A. L., Specks, U., Stone, J. H., Seo, P., Spiera, R. F., Langford, C. A., Hoffman, G. S., Kallenberg, C. G., St Clair, E. W., Tchao, N. K., Ytterberg, S. R., Phippard, D. J., Merkel, P. A., Kaplan, M. J., Monach, P. A.; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. (2015) Neutrophil-related gene expression and low-density granulocytes associated with disease activity and response to treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 67, 1922-1932.
40. Denny, M. F., Yalavarthi, S., Zhao, W., Thacker, S. G., Anderson, M., Sandy, A. R., McCune, W. J., Kaplan, M. J. (2010) A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 184, 3284-3297.
41. Yao, Y., Higgs, B. W., Richman, L., White, B., Jallal, B. (2010) Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNa antibody, in systemic lupus erythematosus. Arthritis Res. Ther. 12 (Suppl 1), S6.
42. Manzi, S., Meilahn, E. N., Rairie, J. E., Conte, C. G., Medsger, Jr., T. A., Jansen-McWilliams, L., D'Agostino, R. B., Kuller, L. H. (1997) Agespecific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408-415.
43. Asanuma, Y., Oeser, A., Shintani, A. K., Turner, E., Olsen, N., Fazio, S., Linton, M. F., Raggi, P., Stein, C. M. (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415.
44. Esdaile, J. M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R., Côte, R., Grover, S. A., Fortin, P. R., Clarke, A. E., Senécal, J. L. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337.
45. Rajagopalan, S., Somers, E. C., Brook, R. D., Kehrer, C., Pfenninger, D., Lewis, E., Chakrabarti, A., Richardson, B. C., Shelden, E., McCune, W. J., Kaplan, M. J. (2004) Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 103, 3677-3683.
46. Warnatsch, A., Ioannou, M., Wang, Q., Papayannopoulos, V. (2015) Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science 349, 316-320.
47. Patel, S., Kumar, S., Jyoti, A., Srinag, B. S., Keshari, R. S., Saluja, R., Verma, A., Mitra, K., Barthwal, M. K., Krishnamurthy, H., Bajpai, V. K., Dikshit, M. (2010) Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generation. Nitric Oxide 22, 226-234.
48. Garcia, R. J., Francis, L., Dawood, M., Lai, Z. W., Faraone, S. V., Perl, A. (2013) Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 65, 1313-1318.
49. Lai, Z. W., Hanczko, R., Bonilla, E., Caza, T. N., Clair, B., Bartos, A., Miklossy, G., Jimah, J., Doherty, E., Tily, H., Francis, L., Garcia, R., Dawood, M., Yu, J., Ramos, I., Coman, I., Faraone, S. V., Phillips, P. E., Perl, A. (2012) N-Acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 64, 2937-2946.
50. Macanovic, M., Sinicropi, D., Shak, S., Baughman, S., Thiru, S., Lachmann, P. J. (1996) The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin. Exp. Immunol. 106, 243-252.
51. Verthelyi, D., Dybdal, N., Elias, K. A., Klinman, D. M. (1998) DNAse treatment does not improve the survival of lupus prone (NZB x NZW)F1 mice. Lupus 7, 223-230.
52. Venkatesh, J., Yoshifuji, H., Kawabata, D., Chinnasamy, P., Stanevsky, A., Grimaldi, C. M., Cohen-Solal, J., Diamond, B. (2011) Antigen is required for maturation and activation of pathogenic anti-DNA antibodies and systemic inflammation. J. Immunol. 186, 5304-5312.
53. Davis, Jr., J. C., Manzi, S., Yarboro, C., Rairie, J., Mcinnes, I., Averthelyi, D., Sinicropi, D., Hale, V. G., Balow, J., Austin, H., Boumpas, D. T., Klippel, J. H. (1999) Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8, 68-76.
54. Knight, J. S., Zhao, W., Luo, W., Subramanian, V., O'Dell, A. A., Yalavarthi, S., Hodgin, J. B., Eitzman, D. T., Thompson, P. R., Kaplan, M. J. (2013) Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J. Clin. Invest. 123, 2981-2993.
55. Knight, J. S., Subramanian, V., O'Dell, A. A., Yalavarthi, S., Zhao, W., Smith, C. K., Hodgin, J. B., Thompson, P. R., Kaplan, M. J. (2015) Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann. Rheum. Dis. 74, 2199-2206.
56. Zeerleder, S., van Bijnen, S., Wouters, D., van Mierlo, G. J., Muus, P. (2013) Neutrophil extracelluar trap formation in PNH patients with and without a history of thrombosis-effects of eculizumab. Blood 122, 1235.
57. Furie, R., Matis, L., Rollins, S. A., Mojcik, C. F. (2001) A single dose, placebo-controlled, double blind, phase I study of the humanized anti-C5 antibody hbG1. 1 in patients with systemic lupus erythematosus. 2001 Innovative Therapies in Autoimmune Diseases, American College of Rheumatology, San Francisco.
58. Wahono, C. S., Rusmini, H., Soelistyoningsih, D., Hakim, R., Handono, K., Endharti, A. T., Kalim, H., Widjajanto, E. (2014) Effects of 1,25(OH) 2D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D. Int. J. Clin. Exp. Med. 7, 22-31.
59. Reynolds, J., Ray, D., Alexander, M. Y., Bruce, I. (2015) Role of vitamin D in endothelial function and endothelial repair in clinically stable systemic lupus erythematosus. Lancet 385 (Suppl 1), S83.
60. Merrill, J. T., Wallace, D. J., Petri, M., Kirou, K. A., Yao, Y., White, W. I., Robbie, G., Levin, R., Berney, S. M., Chindalore, V., Olsen, N., Richman, L., Le, C., Jallal, B., White, B.; Lupus Interferon Skin Activity (LISA) Study Investigators. (2011) Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 70, 1905-1913.
61. Petri, M., Wallace, D. J., Spindler, A., Chindalore, V., Kalunian, K., Mysler, E., Neuwelt, C. M., Robbie, G., White, W. I., Higgs, B. W., Yao, Y., Wang, L., Ethgen, D., Greth, W. (2013) Sifalimumab, a human antiinterferon-a monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 65, 1011-1021.
62. Khamashta, M. Merrill, J. T., Werth, V. P., Furie, R., Kalunian, K., Illei, G. G., Drappa, J., Wang, L., Greth, W. (2014) Safety and efficacy of sifalimumab, an anti IFN-αlpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus. 2014 American College of Rheumatology and Association of Reproductive Health Professionals Annual Meeting, L4 (abs.).
63. McBride, J. M., Jiang, J., Abbas, A. R., Morimoto, A., Li, J., Maciuca, R., Townsend, M., Wallace, D. J., Kennedy, W. P., Drappa, J. (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64, 3666-3676.
64. Kalunian, K., Merrill, J. T., Maciuca, R., Ouyang, W., McBride, J., Townsend, M. J., Park, E. (2012) Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebocontrolled phase 2 study. Arthritis Rheum. 64 (Suppl 10), 2622 (abs.).
65. Fernandez, D. R., Telarico, T., Bonilla, E., Li, Q., Banerjee, S., Middleton, F. A., Phillips, P. E., Crow, M. K., Oess, S., Muller-Esterl, W., Perl, A. (2009) Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 182, 2063-2073.
66. Frese, S., Diamond, B. (2011) Structural modification of DNA-a therapeutic option in SLE? Nat. Rev. Rheumatol. 7, 733-738.
67. Hemmers, S., Teijaro, J. R., Arandjelovic, S., Mowen, K. A. (2011) PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One 6, e22043.
68. Guiducci, C., Gong, M., Xu, Z., Gill, M., Chaussabel, D., Meeker, T., Chan, J. H., Wright, T., Punaro, M., Bolland, S., Soumelis, V., Banchereau, J., Coffman, R. L., Pascual, V., Barrat, F. J. (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937-941.
69. Lauwerys, B. R., Ducreux, J., Houssiau, F. A. (2014) Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) 53, 1369-1376.
70. Mathian, A., Hie, M., Cohen-Aubart, F., Amoura, Z. (2015) Targeting interferons in systemic lupus erythematosus: current and future prospects. Drugs 75, 835-846.
71. Yao, Y., Richman, L., Higgs, B. W., Morehouse, C. A., de los Reyes, M., Brohawn, P., Zhang, J., White, B., Coyle, A. J., Kiener, P. A., Jallal, B. (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60, 1785-1796.
72. Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., Zhong, Z. J., Freimuth, W. W. (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61, 1143-1151.
73. State University of New York-Upstate Medical University. (2008) Treatment of systemic lupus erythematosus with N-acetylcysteine (NAC). ClinicalTrials.gov, NCT00775476. Retrieved October 2, 2015, from https://clinicaltrials.gov/ct2/show/NCT00775476?term=lupus+and+N +Acetyl+cysteine&rank=1.
74. Novo Nordisk A/S. (2009) An investigation of NNC 0151-0000-0000 in subjects with systemic lupus erythematosus. ClinicalTrials.gov, NCT01018238. Retrieved October 2, 2015, from https://clinicaltrials. gov/ct2/show/NCT01018238?term=lupus+and+c5&rank=1.